Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autogenous dentin graft is a bone substitute material derived from a patient's own extracted teeth. Dentin is chemically and structurally similar to human bone, consisting of approximately 70% inorganic hydroxyapatite and 30% organic matrix, which is primarily composed of Type I collagen and growth factors such as Bone Morphogenetic Protein-2 (BMP-2). To prepare the graft, the extracted tooth is cleaned, demineralized, and processed into granules or blocks. It is primarily used in dental procedures such as alveolar ridge preservation (socket preservation) and sinus augmentation. Because it is autogenous, it eliminates the risk of cross-infection or immunological rejection and provides osteoconductive and potentially osteoinductive properties to support new bone formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autogenous dentin graft.